Evotec refines analyst expectations, shares trade under 5 euros on Xetra

Evotec starts the week with a subdued share price below 5 euros on German venues while the analyst consensus still points to markedly higher levels, highlighting a clear gap between market price and broker estimates.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 14:41.

Evotec (DE0005664809) opens the new trading week on Xetra with a muted share price below the 5 euro mark while the analyst consensus remains markedly above the market level. The TecDAX-listed biotech group continues to digest recent capital measures and restructuring steps, according to current broker estimates.

What current prices show

On German platforms such as Stuttgart, Evotec shares recently traded around 4.59 euros, representing a short-term decline of roughly 0.7 percent versus the previous close according to finanzen.net. The stock also trades on Xetra, where MarketScreener quotes the shares at around 4.71 euros with modest intraday movement and volume just under 100,000 shares.

Wallstreet-online data highlight a weak short-term pattern, with Evotec’s share price down about 4.3 percent over seven days and roughly 10.7 percent over the past month. On a one-year view the performance remains clearly negative, with a decline of around 30 percent compared with the previous year, underperforming broader German indices.

Analyst targets remain higher

Analyst data compiled by wallstreet-online show an average target price around 8.45 euros for Evotec, based on 31 published studies that still imply a substantial upside to the current quotation. The distribution remains clearly positive, with most brokers rating the stock at Buy or Outperform according to that overview, despite the recent share price weakness.

Simply Wall St similarly points to a fair value estimate above the current market, citing a calculated intrinsic value of about 6.83 euros per share and describing the stock as trading at a roughly 32 percent discount. That analysis notes that analysts have only slightly adjusted their outlook, fine tuning assumptions around revenue growth, margins and valuation multiples while keeping a fair value estimate near 10 euros.

The product behind the stock

Evotec operates as a drug discovery and development partner for global pharmaceutical and biotechnology companies, focusing on integrated solutions across the R&D chain. The company’s EVT Execute and EVT Innovate segments cover high-throughput screening, medicinal chemistry, preclinical development and a growing portfolio of partnered clinical candidates.

Where the stock trades today

The Evotec shares (DE0005664809) trade on 2026-06-23, 14:30 on the Stuttgart exchange at 4.59 euros.

Key data on the Evotec shares

• Company: Evotec SE
• ISIN: DE0005664809
• WKN: 566480
• Ticker: EVT
• Trading venue: Xetra
• Price (as of 2026-06-23, 14:30): 4.59 euros
• Market cap: 3.5 billion euros (as of 2026-06-23)
• Sector / industry: Health Care / Biotechnology
• Index membership: TecDAX
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell securities.